Roivant Sciences Ltd.
ROIV
$11.31
-$0.05-0.44%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -221.90% | -- | -- | 163.06% | -102.97% |
| Total Depreciation and Amortization | 320.17% | -- | -- | -64.60% | 447.60% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 97.32% | -- | -- | -1,742.33% | 100.24% |
| Change in Net Operating Assets | 164.94% | -- | -- | -607.68% | -24.72% |
| Cash from Operations | 16.74% | -- | -- | -77.79% | 48.46% |
| Capital Expenditure | 55.61% | -- | -- | -176.50% | 1.69% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -51.48% | -- | -- | -- | -100.02% |
| Other Investing Activities | 231.74% | -- | -- | -- | -- |
| Cash from Investing | 136.57% | -- | -- | -113.93% | -99.87% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | -- | -- | 76.14% | -0.04% |
| Issuance of Common Stock | -53.86% | -- | -- | -37.87% | -58.84% |
| Repurchase of Common Stock | -20.21% | -- | -- | -2,210.26% | -763.69% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -100.00% |
| Cash from Financing | 35.10% | -- | -- | -1,924.94% | -113.79% |
| Foreign Exchange rate Adjustments | 54.17% | -- | -- | -220.47% | -128.11% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2,762.21% | -- | -- | -534.89% | -102.57% |